Latest Lausanne Stories
LAUSANNE, Switzerland, November 23, 2010 /PRNewswire-FirstCall/ -- Dr.
The July flight of a solar-powered plane built in Switzerland officially set a trio of world records, authorities with the International Aeronautical Federation (FAI) confirmed on Friday.
The brain's inner network becomes increasingly more efficient as humans mature.
HOUSTON and BOULDER, Colo., Oct.
LAUSANNE, Switzerland, June 1, 2010 /PRNewswire/ -- NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing.
LAUSANNE, Switzerland, April 12 /PRNewswire/ -- Phitek Systems Limited, the global leader in electro-acoustic technologies, announced today that it has selected semiconductor heavyweight STMicroelectronics (ST) as strategic partner in the design and supply of next-generation ANR(TM) Controllers. ANR(TM) Controllers connect to Phitek's ANR(TM) electro-acoustic capsules to provide a complete and best-in-class active noise cancellation solution for use in audio accessory products such as...
LAUSANNE, Switzerland, April 8, 2010 /PRNewswire/ -- Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round.
EPFL's Brain Mind Institute finds clues to the role of brain plaques typical in Alzheimer's patients.
HOUSTON and BOULDER, Colo., Feb.
LAUSANNE, Switzerland, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect.